Lista de obras - Alexander J Muller - Dominio Público Uruguay

A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss of Function Polymorphisms and Indoleamine-2,3-Dioxygenase-2.

artículo científico publicado en 2018

BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner

artículo científico publicado en 1991

Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation.

artículo científico publicado en 2010

Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression

artículo científico publicado en 2007

Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging.

artículo científico publicado en 2008

Cardiac-specific disruption of Bin1 in mice enables a model of stress- and age-associated dilated cardiomyopathy

artículo científico publicado en 2015

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

artículo científico publicado en 2008

En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase ⬇️

artículo científico publicado el 15 de abril de 1993

Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers

scientific article published on 28 September 2018

Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer

artículo científico publicado en 2017

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

artículo científico publicado en 2008

Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.

artículo científico publicado en 2005

Indoleamine 2,3-dioxygenase in immune suppression and cancer.

artículo científico publicado en 2007

Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.

artículo científico publicado en 2008

Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer

article published in 2018

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

scientific article published on 10 September 2018

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

artículo científico publicado en 2005

Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion

artículo científico publicado en 2010

Oncogenic activation of c-ABL by mutation within its last exon.

artículo científico publicado en 1993

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

artículo científico publicado en 2020

Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.

artículo científico publicado en 2006

Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation.

artículo científico publicado en 2003

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

artículo científico publicado en 2006

The gas5 gene is disrupted by a frameshift mutation within its longest open reading frame in several inbred mouse strains and maps to murine chromosome 1.

artículo científico publicado en 1998

The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity

artículo científico publicado en 2009

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

artículo científico publicado en 1990

Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase.

artículo científico publicado en 2010

Lista de obras de Alexander J Muller

A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss of Function Polymorphisms and Indoleamine-2,3-Dioxygenase-2.

BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner

Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation.

Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression

Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging.

Cardiac-specific disruption of Bin1 in mice enables a model of stress- and age-associated dilated cardiomyopathy

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase ⬇️

Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers

Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.

Indoleamine 2,3-dioxygenase in immune suppression and cancer.

Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.

Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion

Oncogenic activation of c-ABL by mutation within its last exon.

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.

Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation.

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

The gas5 gene is disrupted by a frameshift mutation within its longest open reading frame in several inbred mouse strains and maps to murine chromosome 1.

The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase.